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One in three breast cancer patients can be spared debilitating 
chemotherapy by a prognostic molecular test that identifies 
groups of genes governing metastatic dissemination, a group of 
Cape Town oncologists using the method claim.
So far 40 of the 50 samples they have sent off to the 
Netherlands Cancer Institute for the test (10 were spoilt due 
to ‘technical issues’) have given them dramatically improved 
treatment options because of the much improved prognostic 
accuracy.
Where half of these patients would have received 
chemotherapy under traditional prognostication, only 16 
actually received it, with the survival gain jumping from 8.9% 
to 18%.
Not only does the test (known as the MammaPrint 
diagnostic test)  improve the prognosis and quality of life for 
patients but physicians are spared the grinding worry that they 
may be under-treating or over-treating patients.  
Dr Rika Pienaar, a partner in the Panorama oncology practice 
that works in partnership with Tygerberg Hospital’s Breast 
Clinic, said that initially the test was ‘the most challenging 
thing to try’. ‘It can give you a completely different answer to 
what you expected. I actually over-rode the first few tests but 
with time I think we’re now selecting patients for the test better 
and we trust it. It certainly increases your confidence levels 
– you know, having to deal with that fear that you’re under-
treating or over-treating the patient and sparing toxicities to 
patients who are unlikely to benefit from chemo’ she said.
Pienaar said multigene expression analysis approaches 
provided deeper insights into the biological heterogeneity 
of breast cancer, making for a more accurate tool to tailor 
treatments on single patients. The approach was ‘profoundly 
different’ from the current one which consisted of assigning 
treatments on the basis of average expected effects in broad 
categories of patients. This resulted in a tendency to treat 
many patients for the benefit of the few. An approach based on 
average estimates of the effect of chemotherapy lead ‘inevitably 
to over-treatment and consequently, to an increase in the toxic 
burden of adjuvant therapy’.
Tygerberg Hospital’s Breast Clinic chief, Professor Justus 
Apffelstaedt, said that low-risk genetic profile patients were 
now being saved from dreaded chemotherapy. Conversely, 
about one in three patients traditionally believed to be low 
risk (i.e. small tumours with no lymph nodes involved) were 
shown to have a high risk of developing metastases and could 
now be given chemotherapy.
An estimated 8 000 South African women are diagnosed 
with breast cancer every year. Statistics predict about 1 600 
(20%) will die.
Apffelstaedt explained that the ‘MammaPrint’ test, cleared 
by the FDA in America and   recently included in the St 
Gallen criteria for clinical decision-making in breast cancer 
treatment, uses advanced molecular technology to predict 
whether a patient’s breast cancer will metastasise. It does this 
by assessing the activity of 70 genes in the tumour, establishing 
either a ‘low-risk’ or ‘high-risk’ profile. He says experienced 
doctors had observed that some patients with very early 
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cancers, against all expectations, rapidly developed metastases 
and died. This led to several research groups towards the end 
of the 1990s embarking on projects to understand why.
In many cases, although the primary tumour was radically 
excised and tests conducted to ascertain whether metastases 
were present had proved negative, the patient later still 
presented with metastases to organs separate from the primary 
excision site.
This indicated that these metastases were present but 
undetectable by current diagnostic methods at the time of 
treatment. 
How to ‘red-card’ non-lymph node metastases
As early as the 1950s breast cancer researchers first noted 
that about one in three patients whose lymph nodes were 
not infiltrated by cancer still went on to develop metastases 
and die, indicating that breast cancer can spread via the 
bloodstream without initially infiltrating the lymph nodes.
Assessment of the risk of metastases based on the size of 
the tumour, the presence of lymph node infiltration and the 
grade of the tumour is currently still widely used but reflects 
the biological basis of metastases only very loosely. This led to 
the vast majority of patients with breast cancer being put on 
chemotherapy, even though just 10 - 20% of people benefitted. 
This led to asking what other characteristics (besides tumour 
size and lymph node presentation) could ‘red-card’ aggressive 
tumours.
Apffelstaedt, a South African representative on the Breast 
Health Global Initiative, said that in the 1990s molecular 
genetic technologies became available to examine the 
mechanisms underlying the process of metastasis of tumours 
(transcriptional profiling). The activity of groups of genes 
governing the process of metastasis was distilled into 
‘transcriptional profiles’. Examples of these were MammaPrint 
test of the Netherlands Cancer Institute and the Oncotype 
Dx test (USA) and the Rotterdam Profile (University of 
Rotterdam).  ‘On average around 60% of patients have a poor 
and 40% a good prognosis profile. Those with a poor prognosis 
profile have a one in two chance of developing metastases 
and dying within 10 years. They therefore need aggressive 
chemotherapy to improve their survival, even in the case of 
small tumours and no lymph node infiltration,’ he says.
In contrast, those who have a good prognosis profile have a 
4-in-100 chance of developing metastases and dying within 10 
years and therefore do not require aggressive therapy. This all 
added up to one in three patients saved from chemotherapy 
through the genomic transcriptional profiling.
Citing a paper published in Breast Cancer Research and 
Treatment1 Apffelstaedt said tumours with a poor prognosis 
signature were more sensitive to chemotherapy. A meta-
analysis of 1 627 patients confirmed that patients with a good 
prognosis profile derived very little benefit from chemotherapy, 
whereas those with a poor prognosis profile benefitted 
significantly.
Tissue samples are taken from a fresh tumour within 30 
minutes of resection, put in a special medium and air-freighted 
to the Netherlands Cancer Institute for analysis in terms of an 
expert permit obtained from the South African Department of 
Health. This analysis takes about 10 days.
Substantial health economics implications
Apffelstaedt compares the R22 000 price tag for the 
MammaPrint test with the average R110 000 spent on 
chemotherapy and says efforts are afoot to provide the test 
in the state sector. These significant savings raise the ugly 
spectre of a revenue turf war between medical oncologists and 
laboratories. 
Professor Manie de Klerk, head of Clinical Best Practice 
in the Metropolitan Health Group and Qualsa stable, said 
an evaluation of the cost-benefit impact of the test, if used 
stringently against an agreed management algorithm, 
produced a ‘break-even point’ for cost-effectiveness of the test 
(at R22 000 per test) at a chemotherapy cost of between R77 000 
and R107 000 per patient, with the most likely break-even level 
being at about R88 000 for the cost of chemotherapy.
He said this was relevant only after patients, who in all cases 
would receive chemotherapy, had been excluded from multi-
array genetic testing for breast cancer.
This included HER2/Neu-positive patients, triple negative 
(to oestrogen receptors and progesterone receptors and 
HER2/Neu2) patients and those elected for neo-adjuvant 
chemotherapy. Other guideline parameters, such as the specific 
histological type of cancer, tumour size and proper registers 
and review processes, needed to be firmly in place for the test 
to be proposed for funding, he added.
Apffelstaedt is confident that, properly used, transcriptional 
profiling will result in far fewer people presenting with 
metastatic disease. The technology allowed for the testing of 
individual genes, enabling far better treatment selection, often 
using less toxic chemotherapy.
An estimated 8 000 South African women 
are diagnosed with breast cancer every year. 
Statistics predict about 1 600 (20%) will die.
Pienaar said the test ‘improves our ability 
to more precisely predict recurrence and 
allow us to forego unnecessary treatment 
in a large number of patients – without 
denying treatment to those who can most 
benefit from it’.
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Pienaar said the test ‘improves our ability to more precisely 
predict recurrence and allow us to forego unnecessary 
treatment in a large number of patients – without denying 
treatment to those who can most benefit from it’. She described 
transcriptional profiling as ‘a major step in the right direction’.
Very few medical aids pay for the test (those that do require 
pre-authorisation). She described a paper, published in the 
European Journal of Cancer in 2004,2 and uncovered by Izindaba 
background research, in which their claims for transcriptional 
profiling were challenged as ‘pretty dated in terms of research 
progress.’ The paper said that while the transcriptional 
profiling was ‘of utmost importance from a clinical 
perspective’, with potential economic impact on the health 
care system, classifications based on gene expression and on 
more conventional markers performed ‘in parity’. Its authors 
concluded that ‘the conventional markers are by no means 
outperformed as prognostic factors in breast cancer’. They 
said that the real value of the new transcriptional profiling 
data lay in the insights they gave into the important genes and 
pathways that underlie the disease outcome.
Pienaar emphasised that the latest test was ‘not for every 
patient’, with about 60% of breast cancers appropriate for 
the predictive protocol. ‘We’re waiting for the confirmatory 
European trial where they randomised cohorts according to the 
old and new diagnostic protocols, but some of the work is now 
coming through and is being accepted against international 
guidelines.’
Her and Apffelstaedts’ group are the only ones doing the 
work in South Africa. ‘These kind of (genomic) tests are very 
well accepted in the USA and Europe. They will change 
how we think about cancer and how we treat it. We look at 
whether the genes are switched on and discrete. It’s about 
(the tumour’s) behaviour and biological aggressiveness, the 
character and the personality of the cancer, not the size as in 
the old-fashioned way. Breast cancer is one of the best studied 
tumours in the world. The principle must just be applied 
correctly,’ she said.
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